Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The <keyword id="22407175" type="General" weightage="100" keywordseo="U-WIN" source="keywords">U-WIN</keyword> portal, a replication of the <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">Covid-19</keyword> vaccine management system Co-WIN, is set for a pan-India launch likely by the end of August, aiming to maintain an electronic registry of routine immunisations, official sources said. Currently, U-WIN is in pilot mode across all states and Union Territories, except for West Bengal, which is yet to start uploading data, the sources told PTI, adding that it is still under consideration in the state. The U-WIN platform captures every <keyword id="19933690" type="General" weightage="20" keywordseo="vaccination" source="keywords">vaccination</keyword> event for pregnant women and children under the Universal Immunization Programme (UIP). Minister of Finance <keyword id="19916618" type="General" weightage="20" keywordseo="nirmala-sitharaman" source="keywords">Nirmala Sitharaman</keyword> had announced in the interim Budget for 2024-2025 that U-WIN, along with intensified efforts under Mission Indradhanush, will be rolled out nationwide for managing <keyword id="21423640" type="General" weightage="20" keywordseo="immunisation" source="keywords">immunisation</keyword>. "The U-WIN will ensure timely administration of vaccine doses by digitally recording every vaccination event under the Universal Immunisation Programme among all pregnant women and children aged 0-5 years," an official told PTI. "The portal will target 2.9 crore pregnant women and 2.6 crore infants (0-1 years) annually by providing 11 vaccines against 12 vaccine preventable diseases -- diphtheria, measles, rubella, and tetanus through more than 1.2 crore vaccination sessions across the country," the official added. The platform generates a uniform QR-based, digitally verifiable e-vaccination certificate, similar to Covid vaccination certificate, which can be accessed anytime by the citizens through a single click. Vaccination records under UIP are being maintained manually as of now. So this will do away with the hassle of keeping a physical record, the officials explained. It will enable the digitisation of session planning, and updating vaccination status on a real-time basis, they added. "Also, there is no mechanism of individual tracking. There is also lack of awareness among beneficiaries about session location and date especially in urban areas and iniquity in immunisation coverage in states and UTs," another official said. "Besides, another major issue is that immunisation at private health facilities is not recorded," the official added. The U-WIN is going to be the single source of information for immunisation services which will record pregnancy details and outcome, newborn registration and immunisation at birth. It will update vaccination status, and delivery outcome, among others, on real time, the official said. As of July 9, 2024, the pilot has registered 5.33 crore beneficiaries on U-WIN. Over 83.55 lakh vaccination sessions have been digitally conducted, and 18.15 crore vaccine doses have been recorded. The platform aims to reduce zero-dose and left-out children through a name-based tracking mechanism and empower citizens with anytime, anywhere access to vaccination services, particularly benefiting migratory populations, the official said. "The U-WIN portal is likely to be launched pan <keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword> in August end," the official stated. Citizens can self-register for vaccinations via the U-WIN web portal or its Android mobile application, select preferred vaccination centres, and schedule appointments. Automated SMS alerts inform citizens about registration confirmations, administered doses, and upcoming dose reminders, ensuring timely and age-appropriate vaccinations. It also facilitates the creation of Ayushman Bharat Health Account (ABHA) IDs for comprehensive health record maintenance. The U-WIN also supports the frontline workers to digitally record all vaccination events for children and pregnant women for complete, accurate and easy record maintenance, the official said.

Pan-India rollout of U-WIN to track routine immunisations likely by Aug end

The pharmaceutical giant <keyword id="19910149" type="General" weightage="20" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword>'s <keyword id="20040659" type="General" weightage="20" keywordseo="COVID-19-vaccine" source="keywords">COVID-19 vaccine</keyword> is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British Newspaper 'The Telegraph'. AstraZeneca has announced that the <keyword id="19959412" type="General" weightage="20" keywordseo="vaccine" source="keywords">vaccine</keyword> was being removed from markets for commercial reasons. It further said that the vaccine was no longer being made or supplied, having been superseded by updated vaccines that fight new variants. The application to withdraw the vaccine was made on March 5 and came into effect on May 7. The vaccine can be no longer used in the European Union following the company's decision to withdraw its "marketing authorisation." Similar applications will be submitted in the UK and other nations in the coming months that have given a go-ahead to the vaccine, known as Vaxzevria. In recent months, Vaxzevria has come under scrutiny over a very rare side effect, which causes blood clots and low blood platelet counts. In court documents, AstraZeneca in the High Court in February admitted that the vaccine "can, in very rare cases, cause <keyword id="20218859" type="General" weightage="20" keywordseo="TTS" source="keywords">TTS</keyword>". TTS which stands for <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> has been associated with at least 81 deaths in the UK and hundreds of serious injuries. More than 50 alleged victims and grieving relatives have filed a lawsuit against AstraZeneca in a High Court case. AstraZeneca has insisted that the decision to withdraw the vaccine is not related to the case or admission that it can cause TTS and termed the timing a pure coincidence, according to The Telegraph report. "We are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally. Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic," The Telegraph quoted AstraZeneca as saying. In a statement, the pharmaceutical giant said, "As multiple, variant Covid-19 vaccines have since been developed, there is a surplus of available updated vaccines", adding that it has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied, The Telegraph reported. It further announced its decision to initiate the withdrawal of the marketing authorisations for Vaxzevria within Europe. The company said, "We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic." Last week, AstraZeneca reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile. An AstraZeneca spokesperson had stated, "Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines." This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its <keyword id="19896627" type="General" weightage="20" keywordseo="covid" source="keywords">Covid</keyword> vaccine Covishield and Vaxzevria "can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)." Despite these rare occurrences, the pharmaceutical company maintained that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy. Regulatory agencies worldwide continue to assert that the benefits of vaccination outweigh the risks of such extremely rare side effects. SEE ALSO:<a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank"></a> <a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank">Aadhar Housing Finance IPO – Price band to risk factors, all you need to know</a><a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank"></a> <a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank">Top-selling cars in India in April 2024 – Tata Punch continues to dominate</a><a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank">Worldwide tablet shipments grow in Q1 2024 after two years of decline</a>

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

<keyword id="3658" type="General" weightage="100" keywordseo="india" source="Orion">India</keyword> on Tuesday recorded 3038 fresh cases of covid in the last 24 hours with the active caseload standing at 21,179. The COVID cases in India have seen an upward trend in the past few days with the daily fresh infections ranging between 2,994 on April 1 to 3,824 on April 2 and 3,641 on April 3 now dropped to 3038 in the last 24 hours. With 2,069 recoveries in the last 24 hours, total recoveries have increased to 4,41,77,204. India's recovery rate is currently at 98.76 per cent. The daily and weekly positivity rates are 1.84 per cent and 2.49 per cent respectively. A total of 1,894 doses were administered in the last 24 hours. Of the 92.20 crore total tests conducted so far, 1,64,740 tests were conducted in the last 24 hours. Under the Nationwide Vaccination Drive, India has so far administered 220.65 crore Covid-19 <keyword id="24209" type="General" weightage="80" keywordseo="vaccine" source="Orion">Vaccine</keyword> doses (95.20 crores <keyword id="7334317" type="General" weightage="80" keywordseo="second-dose" source="Orion">Second Dose</keyword> and 22.86 crores <keyword id="12813770" type="General" weightage="80" keywordseo="precaution-dose" source="Orion">Precaution Dose</keyword>), of which 9,497 doses were administered in the last 24 hours. In the wake of rising COVID cases in India, Union Health Minister Mansukh Mandaviya on Monday said that Omicron's sub-variant which is circulating in the country has not led to an increase in hospitalisations and there is no need to worry. The Minister said that there is a need to remain vigilant. "We need to remain alert but there is no need to worry. Currently, the sub-variant of Omicron which is circulating in the country hasn't increased hospitalisations," Mandaviya said. The Ministry of Health and Family Welfare has issued revised guidelines for Covid-19 in the wake of the surge of cases in the past week across the country. "Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease," revised guidelines said. "Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease," revised guidelines said. "Seek immediate medical attention if difficulty breathing, High-grade fever/ severe cough, particularly if lasting for more than 5 days. A low threshold is to be kept for those with any of the high-risk features," guidelines discussed and prepared in January said. Additionally, in moderate or severe diseases at high risk of progression, the guidelines recommend, "Consider <keyword id="8775508" type="General" weightage="80" keywordseo="remdesivir" source="Orion">Remdesivir</keyword> for up to 5 days (200 mg IV on day 1 followed by 100 mg IV OD for the next 4 days)". SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/virat-kohli-ms-dhoni-rohit-sharma-rule-brand-endorsements-in-indian-sports-industry/articleshow/99237494.cms">With 30 brands each, Kohli, Dhoni &amp; Rohit Sharma rule Indian sports endorsements</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/harsh-discipline-with-young-children-can-lead-to-lasting-mental-health-problems-says-new-study/articleshow/99238367.cms">Harsh discipline with young children can lead to lasting mental health problems says new study</a>

Remain alert says Union Health Minister as India records 3,038 fresh Covid-19 cases

Not allowing yourself to be peer-pressured into downloading those tiresome dating apps may be the first best precaution you can take to protect your heart. Getting vaccinated for COVID-19 may well be the second, it turns out. A new international study examining the effects of vaccines on millions of patients in the UK, Spain and Estonia found that being vaccinated may be the trick to a healthier heart. In the first month after infection, the researchers found that the risk of <keyword id="25186" type="General" weightage="20" keywordseo="blood-clotting" source="Orion">blood clotting</keyword> plummeted by a whopping 78% in the limbic veins and 47% in the arteries of the vaccinated individuals. Avoiding these complications helped more than halve the <keyword id="32031" type="General" weightage="20" keywordseo="heart-failure" source="Orion">heart failure</keyword> risk among vaxxers compared to the non-vaccinated. <cmsannotation type="cmsannotation" annotationid="What does blood clotting have to do with COVID?" comment="subhead" text="What does blood clotting have to do with COVID?">What does blood clotting have to do with COVID?</cmsannotation> Unfortunately, just having blood inside your body isn’t enough to help you survive; the stuff needs to constantly move and slosh through your blood vessels, transporting and depositing oxygen and other nutrients around like silt on a river edge. However, certain conditions — such as diabetes and obesity — can cause some of your blood to abnormally coagulate, forming giant blockages that prevent your veins and arteries from moving blood around efficiently. This places an extra burden on your heart, which can lead it to fail. Research has shown that COVID-19 infections have the capability to cause unusual blood clots in multiple parts of the body, including the lungs and the legs. This can lead to organ failures, <keyword id="6357661" type="General" weightage="20" keywordseo="heart-attack" source="Orion">heart attack</keyword> and <keyword id="25191" type="General" weightage="20" keywordseo="stroke" source="Orion">stroke</keyword>. Fortunately, simply taking a wee bit of time off to get yourself jabbed by the <keyword id="24209" type="General" weightage="20" keywordseo="vaccine" source="Orion">vaccine</keyword> helps tremendously, it turns out. It wasn’t just heart failure and stroke; being vaccinated also reduced the risk of developing other heart-related diseases. This included scary conditions such as heart attacks and ventricular arrhythmia (an abnormal heartbeat), although this shield only persisted for the first 30 days after the infection. Despite not being at peak efficacy, the vaccine’s protection was potent enough to slash risk of heart failure by nearly 50% for up to a year after vaccination, the study found. This showed that even as the protective halo of the vaccine waned over time, it still continued to pack a punch. <cmsannotation type="cmsannotation" annotationid="Will this squash the vaccine side-effect debate?" comment="subhead" text="Will this squash the vaccine side-effect debate?">Will this squash the vaccine side-effect debate?</cmsannotation> There has been a second-wave of reluctance to take the COVID-19 vaccine, majorly due to concerns of long-term complications that can arise from them. The important thing to note is that while the vaccine can lead to heart issues in some people, it only takes place in extremely rare circumstances. Conversely, one study even showed that vaccination reduced the risk of long-COVID by a massive 67%. The researchers thus hope that these positive heart-related findings will help clear any vaccination hesitations among sceptics. However, more studies need to be conducted to conclusively understand the protection offered by booster doses in different populations. "Our findings probably reflect the fact that the vaccines are effective in reducing infection, and minimise the risk of severe COVID-19," explains study author Núria Mercadé-Besora. "These results could encourage COVID-19 vaccination among hesitant people who are worried about the potential risk of vaccine side effects." The findings of this study have been published in Heart and can be accessed <a href="https://heart.bmj.com/content/early/2024/01/24/heartjnl-2023-323483" data-type="tilCustomLink">here</a>.

COVID-19 vaccine can slash risk of post-infection heart failure by half, study finds

<ul class="summary-list"><li>President Joe Biden tested positive for COVID-19, the White House said.</li><li>Biden was set to speak at the UnidosUS conference in Las Vegas on Wednesday.</li></ul><a target="_blank" class="" href="https://www.businessinsider.com/biden-virtual-roll-vote-explainer-democratic-nomination-drop-out-election-2024-7">President Joe Biden</a> tested positive for COVID-19 on Wednesday, according to the White House."Earlier today following his first event in Las Vegas, President Biden tested positive for COVID-19. He is vaccinated and boosted and he is experiencing mild symptoms. He will be returning to Delaware where he will self-isolate and will continue to carry out all of his duties fully during that time," Press Secretary Karine Jean-Pierre said in a statement provided to Business Insider. "The White House will provide regular updates on the President's status as he continues to carry out the full duties of the office while in isolation."The White House also provided a note from Biden's doctor that said the president tested after having a runny nose, cough, and general malaise. The note said Biden was experiencing mild symptoms and that his respiratory rate, temperature, and blood oxygen levels were normal. It also said he had received a first dose of Paxlovid.Biden, 81, has been in Nevada since Monday night and was set to speak at a conference for UnidosUS in Las Vegas on Wednesday.Janet Murguía, CEO of UnidosUS, told conference attendees that Biden tested positive for COVID-19 after the president was an hour and a half late to his planned speaking event, according to <a target="_blank" class="" href="https://www.cnn.com/2024/07/17/politics/joe-biden-tests-positive-covid-19/index.html">CNN</a>."I was just on the phone with President Biden. And he shared his deep disappointment at not being able to join us this afternoon. The president has been at many events, as we all know, and he just tested positive for COVID," Murguía said at the conference.Biden departed Nevada, a key battleground state for the election in November, on Air Force One on Wednesday, telling reporters at the scene, "I feel good," according to the <a target="_blank" class="" href="https://apnews.com/article/biden-covid-las-vegas-ff29bb071f18b993d20dedccbe2c8fbf">Associated Press</a>.

Biden tests positive for COVID-19

As of now no second Covid-19 booster dose is required, said government sources amid an apparent increase in Covid-19 cases. "First we have to complete the booster drive in the country," said the government sources. India's active caseload currently stands at 2,582, with 134 new cases recorded in the last 24 hours, as per <keyword id="83655" type="General" weightage="80" keywordseo="union-health-ministry" source="Orion">Union Health Ministry</keyword> data. As per ministry data, a total of 220.11 cr vaccine doses (95.13 cr <keyword id="7334317" type="General" weightage="80" keywordseo="second-dose" source="Orion">Second Dose</keyword> and 22.41 cr <keyword id="12813770" type="General" weightage="80" keywordseo="precaution-dose" source="Orion">Precaution Dose</keyword>) have been administered so far under <keyword id="10580665" type="General" weightage="80" keywordseo="nationwide-vaccination-drive" source="Orion">Nationwide Vaccination Drive</keyword>. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/apps/news/series-creators-want-more-money-after-ads-appear-on-netflix/articleshow/96700323.cms">Series creators want more money after ads appear on Netflix</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/thelife/news/pope-benedict-xvi-a-man-at-odds-with-the-modern-world-who-leaves-a-legacy-of-intellectual-brilliance-and-controversy/articleshow/96699003.cms">Pope Benedict XVI: A man at odds with the modern world who leaves a legacy of intellectual brilliance and controversy</a>

No second Covid-19 booster dose required: Govt sources

<ul><li>The Indian immunisation panel is discussing a fourth dose of <keyword id="8764262" type="General" weightage="100" keywordseo="covid" source="Orion">Covid</keyword> vaccine, or a <keyword id="10424474" type="General" weightage="20" keywordseo="second-booster-dose" source="Orion">second booster dose</keyword>. </li><li>India started its booster or precaution dose drive in January 2022 and has so far inoculated over 15 crore Indians in the age group of 15-59 years. </li><li>Only 28% of the eligible population in India have received the first <keyword id="2825536" type="General" weightage="20" keywordseo="booster-dose" source="Orion">booster dose</keyword> so far.</li></ul>Covid-19 cases are once again <a href="https://www.businessinsider.in/science/health/news/indias-case-tally-of-new-omicron-variant-xbb-1-5-reaches-five-heres-what-you-need-to-know/articleshow/96704832.cms">rising across various parts</a> of the world and the Indian government has already started taking precautionary measures. As India has also reported cases of new variants like XBB.1.5, BF.7, the National Technical Advisory Group on Immunisation (NTAGI) is considering to roll out a second booster dose or fourth dose of Covid vaccine for the Indian population. “Discussions have started on the matter of opening a second booster among members of the technical group. There is a section that is keen on allowing another booster dose. They will be minutely going through all the scientific data before making any recommendations,” an expert on one of the committees of NTAGI <a href="https://www.hindustantimes.com/cities/delhi-news/discussions-begin-in-govt-panel-on-2nd-booster-dose-101672684219149.html">said</a>. Last week, doctors of <keyword id="6365835" type="General" weightage="20" keywordseo="Indian-Medical-Association" source="Orion">Indian Medical Association</keyword> (IMA), in a discussion with the union health minister <keyword id="2607815" type="General" weightage="50" keywordseo="mansukh-mandaviya" source="Orion">Mansukh Mandaviya</keyword>, suggested that the government must approve a fourth Covid-19 vaccine for people. <a href="https://www.healthnavigator.org.nz/medicines/c/covid-19-vaccine-booster/">New Zealand</a> is one such country which has approved a second booster dose for people at increased risk of severe illness from COVID-19. The second booster dose is offered at least six months after the previous dose or three months after a COVID-19 infection. <cmsannotation type="cmsannotation" annotationid="Booster dose coverage" comment="subhead" text="Booster dose coverage">Booster dose coverage</cmsannotation> Amid Covid fears, the government is also taking steps to boost the coverage of the first booster dose in the country. India started its booster or precaution dose drive in January 2022 and has given 15 crore booster doses to people in the age group of 15-59 years; and over 69 crore in the age group of 60 plus years, according to <a href="https://www.mohfw.gov.in/pdf/CummulativeCovidVaccinationReport06Jan2023.pdf">data</a> by <keyword id="210071" type="General" weightage="50" keywordseo="ministry-of-health" source="Orion">ministry of health</keyword>. As of January 6, 2023, around 92 crore adults have taken their first dose, while 86 crore vaccines have been administered a second dose in India. Additionally, over 6 crore children aged between 15-18 years have received the first dose, and over 5 crore children in this age group have received the second dose. In the age group of 12 to 14, around 4 crore children have received the first dose, and 3 crore have received the second dose. Other than Covaxin (by Bharat Biotech) and Covishield (by Serum Insitute of India), the government has also approved two more vaccines — Corbevax (by Biological E) and a nasal vaccine named as <a href="https://www.businessinsider.in/science/health/news/covid-19-nasal-vaccine-bharat-biotechs-incovacc-is-the-first-approved-intranasal-vaccine-in-the-world/slidelist/96542239.cms">iNCOVACC</a> (by Bharat Biotech) as booster dose. <cmsannotation type="cmsannotation" annotationid="People reluctant to take booster dose" comment="subhead" text="People reluctant to take booster dose">People reluctant to take booster dose</cmsannotation> Even as discussions around the fourth vaccine are going on, people in various states are reluctant to get their precaution doses. In fact, as per <a href="https://www.hindustantimes.com/cities/delhi-news/discussions-begin-in-govt-panel-on-2nd-booster-dose-101672684219149.html">reports</a>, currently only 28% of the eligible population in India has taken the first booster dose. The West Bengal health department also saw the number of booster dose nosedive, which led to 80,000 Covaxin vaccines expiring by December last year. As per <a href="https://ians.in/news/public-reluctance-to-go-for-covid-booster-dose-worries-bengal-govt/C-1-1550083.html">IANS</a>, the WB health department said that over seven crore people went for the first dose, but the number slid down for the second dose. However, when it came to the third dose aka the booster dose, the number fell to just 1.5 crore. The department official also said this reluctance of people will further lead to more expiration of Covid-19 vaccines in January. A <a href="https://ians.in/news/over-6-in-10-indians-avoiding-covid-booster-due-to-heart-attack-fears-report/C-1-1545504.html">LocalCircles survey</a> also revealed that 64% of Indians are reluctant to take the booster dose of Covid vaccine. The major reason cited by people is rising cases of heart attacks in young people. However, as cases are rising the demand for Covid-19 vaccine seems to be surging and in fact, states like Gujarat and Uttar Pradesh reported a vaccine shortage. "Since the Covid cases had dropped drastically, people had started taking Covid-19 lightly and were less enthusiastic in taking booster doses, so the government, too, was keeping a low stock. As of Monday (December 26) there are 35,000 vaccine bottles available with the state government," <a href="https://ians.in/news/sudden-surge-in-demand-for-vaccine-leads-to-shortage-in-gujarat/C-1-1546640.html">said</a> Nilam Patel, additional director (Health), government of Gujarat. Patel further said, “Till the first week of December (2022), on an average 3,000 vaccinations were taking place on a daily basis but since December 15, all of a sudden, people were turning up in large numbers to take the booster dose." Similarly, the health department of Uttar Pradesh also reported that four government vaccine centres ran out of Covid vaccines, on Wednesday, January 4. However, the department has placed a fresh order of the Covid-19 vaccines and expects it to come by next week. "More than 10 lakh vaccines will be arriving in the state shortly to fulfill the demand across the state. We are also monitoring the COVID-19 situation," Brajesh Pathak, Deputy Chief Minister of UP told <a href="https://www.cnbctv18.com/healthcare/uttar-pradesh-lucknow-government-hopital-run-out-of-covid-doses-india-15580451.htm">PTI</a>. A new <a href="https://economictimes.indiatimes.com/news/newsblogs/covid-outbreak-live-news-coronavirus-india-china-cases-latest-updates-5-january-2023/liveblog/96752025.cms">report</a> also reveals that around 11 types of Covid-19 variant were found in India, when testing international passengers at airports, seaports and landports between December 24 and January 3. (With inputs from PTI and IANS) SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/kreditbee-closes-200-million-series-d-from-advent-international-mufg-bank-others/articleshow/96791309.cms">KreditBee closes $200 million Series D from Advent International, MUFG Bank, others</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/reliance-makes-open-offer-to-acquire-26-stake-in-lotus-chocolate/articleshow/96791043.cms">Reliance makes open offer to acquire 26% stake in Lotus Chocolate</a>

India mulls 2nd Covid booster even as coverage of first dose remains feeble

<keyword id="19895045" type="General" weightage="20" keywordseo="Singapore" source="keywords">Singapore</keyword> is seeing a new <keyword id="21710881" type="General" weightage="20" keywordseo="Covid-19-wave" source="keywords">COVID-19 wave</keyword> as the authorities recorded more than 25,900 cases from May 5 to 11 even as <keyword id="19962428" type="General" weightage="20" keywordseo="Health-Minister" source="keywords">Health Minister</keyword> <keyword id="19895083" type="General" weightage="20" keywordseo="Ong-Ye-Kung" source="keywords">Ong Ye Kung</keyword> on Saturday advised the wearing of masks again. "We are at the beginning part of the wave where it is steadily rising," said Ong. "So, I would say the wave should peak in the next two to four weeks, which means between mid- and end of June," The Straits Times newspaper quoted the minister as saying. The Ministry of Health (MOH) said the estimated number of COVID-19 cases in the week of May 5 to 11 rose to 25,900 cases, compared with 13,700 cases in the previous week. The average daily COVID-19 hospitalisations rose to about 250 from 181 the week before. The average daily intensive care unit (ICU) cases remained low at three cases, compared with two cases in the previous week. The MOH said that to protect hospital bed capacity, public hospitals have been asked to reduce their non-urgent elective surgery cases and move suitable patients to transitional care facilities or back home through Mobile Inpatient Care@Home, an alternative inpatient care delivery model that offers clinically suitable patients the option of being hospitalised in their own homes instead of a hospital ward. Ong urged those who are at greatest risk of severe disease, including individuals aged 60 years and above, medically vulnerable individuals and residents of aged care facilities, to receive an additional dose of the COVID-19 vaccine if they have not done so in the last 12 months. Ong said that if the number of COVID-19 cases doubles one time, Singapore will have 500 patients in its healthcare system, which is what Singapore can handle. However, if the number of cases doubles a second time, there will be 1,000 patients, and "that will be a considerable burden on the hospital system", he pointed out. "One thousand beds is equivalent to one regional hospital," Ong said. "So, I think the healthcare system has to brace ourselves for what is to come." There are no plans for any form of social restrictions or any other mandatory kind of measures for now, as COVID-19 is treated as an endemic disease in Singapore, he said, adding that imposing additional measures would be a last resort. Ong said that with Singapore being a transport and communications hub, it will be one of the cities to get a wave of COVID-19 earlier than others. "So, COVID-19 is just something that we have to live with. Every year, we should expect one or two waves," he said. Globally, the predominant COVID-19 variants are still JN.1 and its sub-lineages, including KP.1 and KP.2. Currently, KP.1 and KP.2 account for over two-thirds of cases in Singapore. As of May 3, the World Health Organisation has classified KP.2 as a variant under monitoring. There are currently no indications, globally or locally, that KP.1 and KP.2 are more transmissible or cause more severe disease than other circulating variants, the MOH said. However, members of the public are urged to stay updated with vaccinations to protect themselves against current and emerging virus strains. The MOH said that to date, about 80 per cent of the local population have completed their initial or additional dose, but have not received a dose within the last year. The ministry added that since COVID-19 vaccination started in 2020 to 2021, the vaccines have consistently been proven to be safe and effective in protecting individuals from severe illness. Billions of doses have been administered globally, and safety monitoring internationally has shown that the vaccine is safe, it said. There have also been no long-term safety concerns with COVID-19 vaccination, and adverse effects from vaccines, including the mRNA vaccines, have all been observed to occur shortly after vaccination, the ministry added. SEE ALSO:<a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank">Motorola Edge 50 Fusion vs OnePlus Nord CE 4 – price, specs and features compared</a><a href="https://www.businessinsider.in/tech/mobile/webstories/iqoo-z9x-5g-with-120hz-display-6000mah-launched-starting-at-12999/slidelist/110176453.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/iqoo-z9x-5g-with-120hz-display-6000mah-launched-starting-at-12999/slidelist/110176453.cms" target="_blank">iQOO Z9x 5G with 120Hz display, 6000mAh launched starting at ₹12,999</a><a href="https://www.businessinsider.in/india/news/woman-loses-54-lakh-in-work-from-home-scam-heres-what-it-is-and-how-to-protect-yourself/articleshow/110166963.cms" target="_blank"></a> <a href="https://www.businessinsider.in/india/news/woman-loses-54-lakh-in-work-from-home-scam-heres-what-it-is-and-how-to-protect-yourself/articleshow/110166963.cms" target="_blank">Woman loses ₹54 lakh in work-from-home scam! Here's what it is and how to protect yourself</a>

Singapore seeing new COVID-19 wave, minister advises wearing of masks

<keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">COVID-19</keyword>, the unwelcome guest that never quite leaves, may well be in the process of ushering in a fresh global wave, with <keyword id="6356662" type="General" weightage="20" keywordseo="singapore" source="Orion">Singapore</keyword> potentially on the front lines. The Singapore government is on alert, with its Ministry of Health reporting a significant rise in COVID-19 cases. There was a doubling of infections in the first half of May, with the numbers increasing from 13,700 in the first week of this month to 25,900 in the second (May 5 to 11). Hospitalisations have also spiked, with average daily admissions rising from 181 to around 250 in the same period. To manage hospital bed capacity, public hospitals have been directed to reduce non-urgent elective surgeries and transfer suitable patients to care facilities. Health Minister <keyword id="19895083" type="General" weightage="20" keywordseo="Ong-Ye-Kung" source="keywords">Ong Ye Kung</keyword> has indicated that Singapore is in the early stages of this wave, which is expected to peak between mid- and end-June. Recognising Singapore's role as a major transport and communications hub, Ong has acknowledged that the city-state is likely to experience COVID-19 waves earlier than other regions. An uptick in infection numbers has also been observed in the neighbouring countries as well, including Philippines. However, no alarming rise in hospitalisation has been reported yet. Regional reports are attributing this surge to new COVID-19 variants, collectively termed FLiRT. This name is based on the technical names for their mutations, one of which includes the letters "F" and "L", and another, the letters "R" and "T". The FLiRT group comprises of variants KP.1, KP.2, KP.3, JN.1.1 and JN.1.7. At present, KP.1 and KP.2 make up over two-thirds of cases in Singapore. While the WHO has classified KP.2 as a variant under monitoring, there is no evidence suggesting these variants are more transmissible or cause more severe illness than existing strains. Nevertheless, Ong has urged high-risk groups, including those aged 60 and above, medically vulnerable individuals, and residents of aged care facilities, to receive an additional COVID-19 vaccine dose if they haven't been vaccinated in the past year. The public has also been advised to consider wearing masks again. Ong emphasised that there are no current plans for social restrictions, as Singapore treats COVID-19 as an <keyword id="21743830" type="General" weightage="20" keywordseo="endemic-disease" source="keywords">endemic disease</keyword>. He noted that additional measures would only be considered as a last resort. “COVID-19 is just something that we have to live with. Every year, we should expect one or two waves,” he said. Meanwhile, 91 cases of the <keyword id="21640619" type="General" weightage="20" keywordseo="FLiRT-variants" source="keywords">FLiRT variants</keyword> have been detected in India. However, there have been no reports of severe cases or unique symptoms associated with these variants so far. (With inputs from TOI)

FLiRT-ing with pandemic! With a sharp rise in COVID cases, could Singapore be witnessing the start of a global wave?

<ul><li> Nearly 600 million more people in India will become eligible for getting the COVID-19 vaccine on May 1.</li><li>At the time, at least 40 million people will be eligible for their second dose and that number would rise every passing day, adding over 65 million people by the end of May.</li><li>According to government guidelines, the second dose needs to be administered within four to eight weeks of the first dose.</li></ul>There will be at least 40 million people eligible for the second dose of COVID-19 vaccine on May 1. According to the Indian government, the interval between the first and second dose should be four to eight weeks. “Most likely, after eight weeks, you should consider your first dose to be a waste of time,” Dr Kunal Sarkar, the chief cardiac surgeon and senior vice chairman of Medica Hospital in Kolkata, told Business Insider. Dr Sarkar’s view echoes the <a href="https://pib.gov.in/PressReleasePage.aspx?PRID=1706597">government guidelines</a> that said that the second dose of Covishield should be administered “not later than stipulated period of 8 weeks.” While a <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00528-6/fulltext">Lancet study</a> has shown that a longer interval may improve the vaccine’s efficacy, the study itself recommended a 12-week interval between doses. Moreover, the vaccines currently in use are those that have been given emergency approval and it is wise to err on the side of caution especially with new variants of the virus emerging. “With COVAXIN, they maintain that the interval should be four weeks. With Covishield, as per their trial data, even they said four weeks. Then, based on certain experiences in the UK, it was stretched to six weeks,” said Sarkar. “Now, because of the irregularity in supply, it is anybody's guess… By and large, we are afraid if it stretches beyond eight weeks or so, then will the two-dose concept still remain valid? There is no data.” In order to ensure that people who already have the first dose do not get pushed behind in the queue, the Indian government should allow for separate counters and dedicated slots for people who are eligible for the second dose. This would be easier said than done given the <a href="https://www.businessinsider.in/india/news/vaccine-shortage-in-india-18-people-could-not-find-covid-19-dose-when-they-went-for-vaccination-in-first-ten-days-of-april-says-survey/articleshow/82014884.cms">current shortage </a>of vaccine supply across many states. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Description </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Number of doses </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Number of first doses given as of April 1 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">58,354,638 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Number of second doses given between April 2 to April 28 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">16,572,965 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10-day average for second dose administration as of April 28 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">833,782.3 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">People likely to get vaccinated between April 29 and April 30 as per 10-day average </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1,667,564.6 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Number of people likely to be eligible for the second dose on May 1 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">40,114,108.4 </td></tr></tbody></table>Source: Data from the Ministry of Health and Family Welfare (MoHFW) On May 1, as the country opens up its vaccination drive to everyone above the age of 18 years, 600 million additional people will become eligible. This could lead to another crisis as another 40 million will already be waiting in the queue for the second dose. And that number will rise with every passing day, as the 65 million people above the age of 45 — who got the first dose after April 1 — complete their stipulated time of four to eight weeks and join the queue for the second dose. If they don’t get vaccinated in time, they will have to begin the vaccination cycle all over again. <div type="image" title="rush of people vaccine_edited" msid="82304037" hostid="261" caption="&amp;lt;p&amp;gt;People queue up to get their second dose of Covid-19 vaccine at the Swarna Bharathi Indoor Stadium in Visakhapatnam on April 28&amp;lt;/p&amp;gt;"></div> According to Dr Marcus Ranney, founder and chief executive of Human Edge, the need to separate the people coming in for vaccination is also important to avoid the spreading of the virus at the centres. “As the window will open to 18-year-olds, they very clearly need to have centres that are earmarked for different populations. If they try and serve everyone from the same place, it’s just going to create chaos and may even fuel a much larger spread,” he told Business Insider. One way to stall the chaos is to prioritise those who need the second shot. Another filter that can be used is to ask those who may have been infected by COVID-19 in recent weeks to <a href="https://www.businessinsider.in/science/health/news/if-you-have-just-recovered-from-covid-19-experts-say-you-dont-need-to-join-in-on-the-rush-for-vaccination-immediately/articleshow/82302460.cms">stay out of the queue</a>. “What hasn’t been used as well as we could have done is the same methodology used with polio and other types of vaccines, which was more door to door — particularly for the elderly folks,” said Ranney. All in all, the government needs to come out with clear guidelines to ensure no one is left behind, and not one precious dose goes to waste — especially since India has already wasted 4.6 million doses till April 11. <div type="image" title="vaccine queue_edited" msid="82304124" hostid="261" caption="&amp;lt;p&amp;gt;People wait in a long queue to get vaccinated in Visakhapatnam on April 27&amp;lt;/p&amp;gt;"></div> <cmsannotation type="cmsannotation" annotationid="There is going to be a crazy rush at vaccination centres in the absence of proper guidelines" comment="subhead" text="There is going to be a crazy rush at vaccination centres in the absence of proper guidelines">There is going to be a crazy rush at vaccination centres in the absence of proper guidelines</cmsannotation> This has become evident from the response to the opening up of online booking of vaccination slots. The government opened up registrations for people between the ages of 18 to 44 on April 28. And, before things could even take off, registration was delayed from midnight to 4:00 pm. According to the government, more than 3.5 million people registered within the first hour of the launch. But when it came to being able to book an appointment, they passed the buck onto state governments and private vaccination centers. When the floodgates opened, the CoWIN app, Aarogya Setu app and UMANG app’s servers crashed. Many of those who got the chance to register via the CoWIN website, <a href="https://www.businessinsider.in/tech/apps/news/cowin-website-is-back-up-after-an-early-crash-finding-a-vaccination-slot-may-still-be-difficult/articleshow/82291583.cms">never found an open slot. </a> Even if the government were to take no new bookings, and only focus on those needing second shots at all centres, at the current rate of vaccination, it would take 48 days to just go through that lot. In such a scenario, it is not unimaginable that those who need the second shot never get the slot before their 12-week deadline. <cmsannotation type="cmsannotation" annotationid="The other challenge will be allocating the limited vaccine supplies" comment="subhead" text="The other challenge will be allocating the limited vaccine supplies">The other challenge will be allocating the limited vaccine supplies</cmsannotation> This would not have been a concern if India had enough vaccines to go around for everyone who wants it. However, that’s not the case because the government dragged its feet in placing the orders. On April 23, the government pledged to increase the monthly production of doses to around 100 million doses by September with the rate of immunisation slowing down amid rising cases. When the government opened up jabs for those above the age of 45 from May 1, it had expected the imported lot of Russia’s Sputnik V COVID-19 vaccine to arrive by then. While Russia is now sticking to the date, it is not clear how many doses will come in, especially after a brief attempt to <a href="https://www.reuters.com/world/india/exclusive-india-get-russias-sputnik-v-vaccine-only-by-end-may-2021-04-22/">delay the supply</a> to the end of May. Having to repeat the first doses for even one person is a waste of precious resources. Managing a pandemic was never going to be easy. Imagining scenarios and preparing for the possibilities is the only way to keep things from spiraling out of control. The updated version of the story includes additional opinions from Dr Kunal Sarkar and the Lancet study, which recommended an interval of 12 weeks between two vaccine doses. SEE ALSO: <a href="https://www.businessinsider.in/tech/apps/news/cowin-website-is-back-up-after-an-early-crash-finding-a-vaccination-slot-may-still-be-difficult/articleshow/82291583.cms">CoWIN website is back up after an early crash⁠ — finding a vaccination slot may still be difficult</a> <a href="https://www.businessinsider.in/india/news/covid-19-vaccine-price-sc-wants-the-indian-government-to-explain-about-covishield-and-covaxin-pricing/articleshow/82272913.cms">Supreme Court wants the Indian government to explain vaccine pricing — and clarify how many doses it will need as coverage expands from May 1</a> <a href="https://www.businessinsider.in/international/news/australia-suspends-incoming-flights-from-india-until-may-15/articleshow/82271595.cms">Australia suspends incoming flights from India until May 15 — IPL cricketers, coaches and broadcasters left in a bind</a>

India may end up wasting millions of COVID-19 vaccine doses if there is no separate queue for second shots

<ul class="summary-list"><li>The Johnson &amp; Johnson single-dose COVID-19 vaccine is no longer available in the US. </li><li>Over two years after it was first approved, the last batch of doses has been thrown out. </li></ul>At the height of the COVID-19 pandemic, Americans were clamoring to get vaccinated as soon as they could.But now, millions of doses of the Johnson &amp; Johnson vaccine are getting tossed in the trash because no one's using them. More than 2 years after Johnson &amp; Johnson's vaccine was first authorized for emergency use by the FDA, it is now no longer available anywhere in the US, <a href="https://www.ny1.com/nyc/all-boroughs/news/2023/05/15/johnson---johnson-covid-vaccine-no-longer-available-us" target="_blank" rel="noopener">according to the CDC</a>. Over 31.5 million doses of the J&amp;J vaccine have been distributed across the country since March 2021 — 19 million of which made it into Americans' arms, <a href="https://www.cnn.com/2023/05/15/health/johnson-johnson-covid-vaccine-end/index.html" target="_blank" rel="noopener">CNN reported</a>.The 12.5 million remaining doses — nearly a third of the total produced — expired on May 7, and the CDC has told all vaccine providers to get rid of them. Though the J&amp;J vaccine was the least popular of the three vaccines available in the US, its final demise is still a stark contrast to the early days of COVID-19 vaccination when <a href="https://www.businessinsider.com/rich-poor-covid-vaccine-disparity-2021-2">rich people were gaming the system</a> to get vaccinated before their turn.During the height of the pandemic, <a href="https://www.businessinsider.com/how-to-get-coronavirus-vaccine-without-skipping-line-2021-1">young people also showed up at pharmacies</a> just before closing time, hoping to snag soon-to-expire shots before they were trashed.And even for those who followed the rules, wait times for vaccine appointments at the height of the public health crisis were often days — or even weeks. The end of the J&amp;J vaccine comes less than a week after the <a href="https://www.hhs.gov/about/news/2023/05/09/fact-sheet-end-of-the-covid-19-public-health-emergency.html" target="_blank" rel="noopener">US Department of Health and Human Services</a> officially ended the COVID-19 public health emergency as the Biden administration winds down its COVID-19 response. The World Health Organization recently said that COVID-19 is now a disease we'll need to learn to live with — though it warned that there's still a risk of a relapse with a new variant if countries slack off their preventative measures. Correction: May 26, 2023 — An earlier version of this story misidentified the FDA's decision on the Johnson &amp; Johnson vaccine. The vaccine was authorized for emergency use.

People used to fight over getting a COVID-19 vaccine. Now millions of doses are getting tossed in the trash because no one's using them.

<ul><li>12 billion COVID-19 vaccine doses rolled out by <keyword id="23764" type="General" weightage="100" keywordseo="global" source="Orion">Global</keyword>.</li><li>The three-day event is being co-hosted by the Pune-based <keyword id="95879" type="General" weightage="50" keywordseo="serum-institute-of-india" source="Orion">Serum Institute of India</keyword>.</li><li>According to Global, the roll-out of more than 12 billion COVID-19 vaccine doses is the largest and fastest in history.</li></ul><keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword> (WHO) director-general Dr Tedros Adhanom Ghebreyesus on Thursday said global roll-out of more than 12 billion COVID-19 vaccine doses is the largest and fastest in human history. Addressing the annual general meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) virtually, he flagged the issue of inequities in access to COVID-19 vaccines. The three-day event is being co-hosted by the Pune-based Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, said a statement. Global roll-out of more than 12 billion COVID-19 vaccine doses is the largest and fastest in history with an estimated 60 per cent doses produced by manufacturers in developing countries. Despite this achievement, stark inequities in access to COVID-19 vaccines remain," he said. "These inequities are due partly to the fact that globally vaccine production is too concentrated. To address this, the WHO and our partners have established the mRNA Tech Transfer hub in South Africa to facilitate the know-how in low &amp; middle-income countries," Ghebreyesus said. <keyword id="383467" type="General" weightage="50" keywordseo="adar-poonawalla" source="Orion">Adar Poonawalla</keyword>, CEO of SII, said it was a proud moment for his company to co-host the 23rd DCVMN annual general meeting in <keyword id="2094" type="General" weightage="50" keywordseo="pune" source="Orion">Pune</keyword>. "Today, the world is more aware and focused on chalking out an ambition-to-action roadmap for future pandemic preparedness. For that, building the infrastructure and regulations to ensure global equity and timely access to vaccines is the foremost priority," Poonawalla said. Union Minister for Health and Family Welfare Mansukh Mandaviya delivered the inaugural address. DCVMN is an international alliance of manufacturers from developing countries who are engaged in innovation, research, development, manufacturing and supply of high-quality vaccines to 170 countries. The organisation aims to protect people against known and emerging infectious diseases globally by increasing the production of high-quality vaccines in developing countries. SEE ALSO: <a href="https://www.businessinsider.in/personal-finance/news/should-you-buy-gold-this-dhanteras/articleshow/94997439.cms">Should you buy gold this Dhanteras?</a> <a href="https://www.businessinsider.in/business/corporates/news/tata-consumer-products-profit-grows-36-to-355-crore-in-q2-fy23/articleshow/94992535.cms">Tata Consumer Products profit grows 36% to ₹355 crore in Q2 FY23</a>

You Searched For "covid 19 vaccine second dose" and got 12 results

Pan-India rollout of U-WIN to track routine immunisations likely by Aug end

PTI

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

ANI

Remain alert says Union Health Minister as India records 3,038 fresh Covid-19 cases

ANI

COVID-19 vaccine can slash risk of post-infection heart failure by half, study finds

Ankush Banerjee

Biden tests positive for COVID-19

Kelsey Vlamis,Brent D. Griffi…

No second Covid-19 booster dose required: Govt sources

ANI

India mulls 2nd Covid booster even as coverage of first dose remains feeble

Vaamanaa Sethi

Singapore seeing new COVID-19 wave, minister advises wearing of masks

PTI

FLiRT-ing with pandemic! With a sharp rise in COVID cases, could Singapore be witnessing the start of a global wave?

Kunal Kambli

India may end up wasting millions of COVID-19 vaccine doses if there is no separate queue for second shots

Prabhjote

Sriram

People used to fight over getting a COVID-19 vaccine. Now millions of doses are getting tossed in the trash because no one's using them.

Grace Eliza Goodwin

Global rollout of 12 billion Covid-19 vaccine doses largest-ever, but access is an issue: WHO

IANS

Popular Keywords

Buying Guides